All In Biotech

BLA 761122 · Glaxosmithkline

Nucala

Mepolizumab · Subcutaneous · Interleukin-5 Antagonist

Orphan

Last checked: Nov 19, 2026Latest source record: Aug 6, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Jun 6, 2019

Approved uses

3

Original approval plus efficacy supplements

Registered trials

87

34 Phase 3, 15 recruiting

FAERS reports

50,431

31,676 serious, 4,180 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 6, 2025.

NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: • Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. ( 1.1 ) • Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) • Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.3 ) • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.4 ) • The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. ( 1.5 ) Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 , 1.3 ) 1.1 Maintenance Treatment of Severe Asthma NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype [see Use in Specific Populations ( 8.4 ), Clinical Studies ( 14.1 )] . Limitations of Use NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions ( 5.2 )] . 1.2 Maintenance Treatment of Chronic Rhinosinusitis with Nasal Polyps NUCALA is indicated for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients aged 18 years and older with inadequate response to nasal corticosteroids. 1.3 Maintenance Treatment of Chronic Obstructive Pulmonary Disease NUCALA is indicated for the add-on maintenance treatment of adult patients with...

Mechanism: Mepolizumab is an IL-5 antagonist (IgG1 kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Mepolizumab binds to IL-5 with a dissociation constant of 100 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface. Inflammation is an important component in the pathogenesis of asthma, CRSwNP, COPD, EGPA, and HES. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators...

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NUCALA · MEPOLIZUMAB 100MG/ML · INJECTABLE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mepolizumab" as an intervention, any sponsor and status, largest first.

All 87 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • asthma12,892
  • dyspnoea10,717
  • wheezing7,204
  • product dose omission issue6,869
  • cough5,147
  • therapeutic product effect incomplete5,092
  • drug ineffective4,736
  • pneumonia4,726
  • loss of personal independence in daily activities4,281
  • fatigue3,151
  • sleep disorder due to a general medical condition3,148
  • off label use3,137

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20092
20121
20135
20147
201518
2016579
20171,547
20183,014
20194,612
20205,676
20216,089
20224,725
20235,642
20247,767
20257,636
20263,110

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nucala (Mepolizumab)

2024 spending

$318M

Beneficiaries

9,062

72,258 claims

Per beneficiary

$35,081

$3,679.11 per unit

View as table
YearSpending
2020$86,623,799
2021$132,108,367
2022$193,350,671
2023$260,986,344
2024$317,907,428

Part B: Nucala (Mepolizumab) · HCPCS J2182

2024 spending

$267M

Beneficiaries

8,671

78,535 claims

Per beneficiary

$30,829

2024 ASP limit $30.47 per unit

View as table
YearSpending
2020$189,665,582
2021$210,518,708
2022$232,903,955
2023$255,126,934
2024$267,320,860

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 259 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.